Skip to main content

Table 1 Patient and tumour characteristics

From: Pretreatment levels of the serum biomarkers CEA, CYFRA 21–1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients

Variables

Demographics

N

%

Sex

Male

39

67.2

 

Female

19

32.8

Age (ys)

<60

26

44.8

 

≥60

32

55.2

Smoking status

Never smoker

14

24.1

 

Active

20

34.5

 

Ever smoker

24

41.4

Histology

Adenocarcinoma

41

70.7

 

Squamous

6

10.3

 

Unknown

11

19.0

Stage

I-II

5

8.6

 

IIIa

2

3.5

 

IIIb

12

20.7

 

IV

39

67.2

Performance status

0-1

23

39.7

 

2-3

5

8.6

 

Unknown

30

51.7

Prior treatment

0

12

20.7

 

1

28

48.3

 

2

15

25.9

 

3

2

3.4

 

4

1

1.7